NCT06059131View on ClinicalTrials.gov

Effect of a Specific Aquaporin-1 Inhibitor on Vascular Oxidative Stress in Healthy Volunteers

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Oxidative StressCardiovascular DiseasesBacopaside IIBacopa MonnieriEndothelial DysfunctionAquaporin 1AQP1
Interventions
OTHER

KeenMind

320 mg/d (2 capsules/d) during 3 months

OTHER

Placebo

320 mg/d (2 capsules/d) during 3 months

Trial Locations (1)

1200

Cliniques Universitaires Saint Luc, Brussels

All Listed Sponsors
collaborator

Université Catholique de Louvain

OTHER

lead

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER